All Alzheimer's articles
-
OpinionMoving beyond protein structure
Efforts to understand how intrinsically disordered regions interact have produced a variety of answers
-
OpinionLetters: September 2023
Readers estimate the contribution of lithium mining on power consumption, consider Alzheimer’s antibody therapies and more
-
BusinessAntibodies face Alzheimer’s reality
Companies are convincing regulators, but will doctors use them, and will providers pay for them?
-
BusinessBiogen to cut 1000 more jobs by 2025
Biotech giant has also agreed to buy Reata Pharmaceuticals for $7.3 billion
-
ResearchTell-tale protein fragment discovered in Alzheimer’s patients could be basis for blood test
Tau protein fragment could track progress of the disease
-
OpinionRegulators must follow their heads, not their hearts
The 2019 US approval of antibiotic Recarbrio seems not to have met the normally expected standards
-
BusinessSecond Alzheimer’s antibody approved in the US
Biogen–Eisai’s lecanemab can slow disease progression a little, but at significant cost and risk of side effects
-
BusinessAlzheimer’s antibody engenders anticipation
Tantalising press-released data on Biogen and Eisai’s lecanemab prompt questions without firm answers
-
OpinionAlzheimer’s, amyloid and abandoned antibodies
Biogen’s aducanumab is stumbling into obscurity. Where does that leave the amyloid hypothesis?
-
OpinionWhen regulatory cooperation goes too far, we all lose
Were FDA staff unduly influenced by Biogen in approving Alzheimer’s antibody?
-
BusinessAlzheimer’s antibody gets surprise US approval
Good news for industry and future drug approvals, but physicians doubt it will be effective for most patients
-
ResearchBiochemical mystery unfolds as elemental metals found in Alzheimer’s patients’ brains
In a discovery that raises more question than it answers, researchers have found zero-oxidation-state iron and copper deposits inside amyloid plaques
-
BusinessRegulatory panel unconvinced by Alzheimer’s antibody evidence
US FDA advisors vote against approving Biogen’s aducanumab on the basis of incomplete data analysis
-
NewsSwipe right to help in the fight against Huntington’s disease
Citizen science project improves understanding of protein misfolding disorders like Huntington’s and Alzheimer’s diseases
-
-
ResearchAlzheimer’s therapy has click chemistry use, then remove, brain copper build-ups
In situ drug synthesis catalysed by endogenous copper
-
BusinessSixth in a line of Alzheimer’s drugs fails in trials
Treatments designed to stop amyloid peptide formation all seem to cause cognitive impairment rather than prevent it
-
PodcastAmantadine
Katrina Krämer investigates how one of the smallest small molecule drugs around saved Jeanna Giese's life
-
ResearchAlzheimer’s linked to infection of the brain by gum disease bacterium
Drug firm is developing treatment to inhibit bacterial enzymes believed to be damaging important protein
-
ResearchScorpion venom peptide engineered to sting brain disorders
Structure used to escort nanoparticles across blood–brain barrier also resists protease degradation